APIs and Finished Drug Products
Filling America’s Medicine Cabinet
Phlow leverages its R&D lab co-located next to the United States Pharmacopeia (USP), its state-of-the-art pharmaceutical manufacturing facilities, and its extensive partnership network to deliver advanced manufacturing solutions, including continuous manufacturing capabilities to provide a reliable and affordable supply of high-quality essential medicines.
Leading the Way to National Medicine Supply Chain Security
Phlow’s initial focus is to use advanced development and manufacturing methods to reshore critical APIs and reduce dependency on foreign supply chains. Phlow’s program helps secure our Nation’s essential medicine supply and medical countermeasures by bringing the development and manufacturing of these critical national pharmaceutical ingredient assets back home. Phlow has end-to-end expertise and capabilities to enable the advanced development and manufacturing of formulation-ready APIs for small molecule essential medicines and novel therapeutics. By providing innovative and stable solutions for onshore API production, Phlow helps the U.S. government protect the health of Americans with domestically-supplied life-changing APIs needed for lifesaving care.
To date, Phlow has delivered more than 2 million doses of essential medicines to the Strategic National Stockpile (SNS) to support the U.S. government’s emergency response capabilities for the health of all Americans.
Putting Pediatric Patients First
A Sustainable, Domestic Supply of Life-Changing Medicines
The care of America’s children has been unnecessarily impacted by shortages of essential medicines, we are on a mission to fix this problem. Phlow’s finished drug portfolio is designed to start addressing this crisis and currently includes the following medicines with additional under development: